Humanization of an Anti-Human TNF-α Monoclonal Antibody
Author Information
Author(s): Chiu Wei-Chun, Lai Ya-Ping, Chou Min-Yuan
Primary Institution: Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan
Hypothesis
Can a murine monoclonal antibody against human TNF-α be humanized while retaining its binding affinity and bioactivity?
Conclusion
The humanized antibody h357 retains high antigen binding affinity and effectively inhibits disease progression in a mouse model of arthritis.
Supporting Evidence
- The humanized h357 IgG1 was stably expressed in a mammalian cell line.
- h357 IgG significantly inhibited disease progression in a mouse model of collagen antibody-induced arthritis.
- The humanization process did not alter the TNF-α binding strength of the parental mouse antibody.
- Both m357 and h357 IgGs effectively neutralized TNF-α-mediated cytotoxicity in L929 cells.
Takeaway
Scientists made a mouse antibody that fights a protein causing inflammation in humans and changed it to work better in people without causing side effects.
Methodology
The study involved humanizing a murine antibody through variable domain resurfacing and testing its effects in a mouse model of arthritis.
Potential Biases
Potential bias in the selection of antibody variants and the experimental model used.
Limitations
The study primarily focused on in vitro and mouse models, which may not fully predict human responses.
Participant Demographics
Mice used in the study were male DBA/1J mice, aged 8-10 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website